Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy

American Journal of Cardiology

Volumn 103, Issue 3, 2009, Pages 369-374

  Pearson, Thomas A ^a   Ballantyne, Christie M ^b   Veltri, Enrico ^c   Shah, Arvind ^c   Bird, Steven ^c   Lin, Jianxin ^c   Rosenberg, Elizabeth ^c   Tershakovec, Andrew M ^c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE; FLUINDOSTATIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ADD ON THERAPY; ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58749090559     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.09.090     Document Type: Article

References (30)

1. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon III R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
2. Ballantyne C.M., and Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 6 (2005) 21-29
3. Black S., Kushner I., and Samols D. C-reactive protein. J Biol Chem 279 (2004) 48487-48490
4. Zhou Z., Rahme E., and Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 151 (2006) 273-281
5. Gotto Jr. A.M. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 96 suppl (2005) 34F-38F
6. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., Pfeffer M.A., and Braunwald E. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
7. Darkes M.J., Poole R.M., and Goa K.L. Ezetimibe. Am J Cardiovasc Drugs 3 (2003) 67-76
8. Dujovne C.A., Ettinger M.P., McNeer J.F., Lipka L.J., LeBeaut A.P., Suresh R., Yang B., and Veltri E.P. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1092-1097
9. Goldberg A.C., Sapre A., Liu J., Capece R., and Mitchel Y.B. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79 (2004) 620-629
10. Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P., Suresh R., Sun S., and Veltri E.P. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
11. Bays H.E., Ose L., Fraser N., Tribble D.L., Quinto K., Reyes R., Johnson-Levonas A.O., Sapre A., and Donahue S.R. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
12. Melani L., Mills R., Hassman D., Lipetz R., Lipka L., LeBeaut A., Suresh R., Mukhopadhyay P., and Veltri E. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 24 (2003) 717-728
13. Ballantyne C.M., Houri J., Notarbartolo A., Melani L., Lipka L.J., Suresh R., Sun S., LeBeaut A.P., Sager P.T., and Veltri E.P. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107 (2003) 2409-2415
14. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
15. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., and Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial. Mayo Clin Proc 80 (2005) 587-595
16. Brohet C., Banai S., Alings A.M., Massaad R., Davies M.J., and Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 21 (2005) 571-578
17. Farnier M., Volpe M., Massaad R., Davies M.J., and Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 102 (2005) 327-332
18. Cruz-Fernandez J.M., Bedarida G.V., Adgey J., Allen C., Johnson-Levonas A.O., and Massaad R. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 59 (2005) 619-627
19. Gagne C., Bays H.E., Weiss S.R., Mata P., Quinto K., Melino M., Cho M., Musliner T.A., and Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 90 (2002) 1084-1091
20. Pearson T., Ballantyne C., Sisk C., Shah A., Veltri E., and Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 99 (2007) 1706-1713
21. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (2008) 1431-1443
22. Ray K.K., Cannon C.P., Cairns R., Morrow D.A., Rifai N., Kirtane A.J., McCabe C.H., Skene A.M., Gibson C.M., Ridker P.M., and Braunwald E. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 46 (2005) 1417-1424
23. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
24. Albert M.A., Danielson E., Rifai N., and Ridker P.M. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
25. Ansell B.J., Watson K.E., Weiss R.E., and Fonarow G.C. hsCRP and HDL Effects of Statins Trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels: a clinical investigation. Heart Dis 5 (2003) 2-7
26. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 49 (2007) 2003-2009
27. Tuzcu E.M., and Nicholls S.J. Statins targeting inflammation by lowering low-density lipoprotein?. J Am Coll Cardiol 49 (2007) 2010-2012
28. Robinson J.G., Smith B., Maheshwari N., and Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction?. A meta-regression analysis. J Am Coll Cardiol 46 (2005) 1855-1862
29. Davis H.R., and Veltri E.P. Zetia: inhibition of Niemann-Pick C1 like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 14 (2007) 99-108
30. Abate N., Catapano A.L., Ballantyne C.M., Davidson M.H., Polis A., Smugar S.S., and Tershakovec A.M. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: results of two subgroup analysis. J Clin Lipidol 2 (2008) 91-105